Published in Mol Cancer Ther on January 26, 2010
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors | NCT01125891
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther (2010) 1.34
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 1.12
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther (2012) 1.02
Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Mol Cancer (2013) 1.00
Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells. Mol Cell Biol (2011) 0.93
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res (2014) 0.88
Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes. Mol Cell Proteomics (2016) 0.85
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol (2015) 0.84
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs (2013) 0.83
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res (2015) 0.81
The Catalytic Subunit of DNA-Dependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry. Neoplasia (2015) 0.79
PLK1, A Potential Target for Cancer Therapy. Transl Oncol (2016) 0.77
Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. Mol Cell Biol (2016) 0.75
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther (2005) 3.28
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell (2011) 2.78
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol (2009) 2.67
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther (2008) 2.38
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res (2004) 2.14
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res (2003) 2.08
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res (2007) 2.07
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A (2012) 1.90
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst (2003) 1.83
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res (2002) 1.79
A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn (2010) 1.71
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protoc (2007) 1.61
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res (2011) 1.59
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res (2005) 1.59
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res (2003) 1.59
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther (2005) 1.57
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res (2009) 1.53
A highly enantioselective intramolecular Michael reaction catalyzed by N-heterocyclic carbenes. Angew Chem Int Ed Engl (2007) 1.52
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.47
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 1.47
Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol (2005) 1.44
Tandem oxidation of allylic and benzylic alcohols to esters catalyzed by N-heterocyclic carbenes. Org Lett (2007) 1.38
Promising developments in targeted therapies for non-small-cell lung cancer. Clin Lung Cancer (2002) 1.38
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther (2010) 1.34
Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol (2003) 1.33
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol (2013) 1.32
Discovering New Reactions with N-Heterocyclic Carbene Catalysis. Aldrichimica Acta (2009) 1.32
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol (2008) 1.30
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One (2013) 1.29
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol (2009) 1.29
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett (2013) 1.22
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther (2006) 1.22
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer (2010) 1.21
Protonation of Homoenolate Equivalents Generated by N-Heterocyclic Carbenes. Synthesis (Stuttg) (2008) 1.21
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol (2011) 1.21
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res (2004) 1.20
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Mol Cancer Ther (2005) 1.19
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res (2005) 1.19
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther (2008) 1.18
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther (2011) 1.18
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.16
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther (2007) 1.13
An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther (2003) 1.11
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.11
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol (2007) 1.10
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol (2012) 1.09
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs (2006) 1.08
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07